



August 13, 2012

## **ImmunoCellular Therapeutics' ICT-107 featured on CNN's Sanjay Gupta MD**

LOS ANGELES, CA – ImmunoCellular Therapeutics (NYSE MKT: IMUC) a clinical stage biotechnology company that is focused on developing new immune-based products to treat cancer, announced today that it was featured on CNN's Sanjay Gupta MD last weekend. The show profiled IMUC's dendritic cell-based vaccine, ICT-07, which is currently undergoing a Phase IIb clinical trial treating newly diagnosed patients with glioblastoma multiforme, an aggressive, terminal form of brain cancer.

Dr. Sanjay Gupta is the multiple Emmy®-award winning chief medical correspondent for CNN. Gupta, a practicing neurosurgeon, plays an integral role in CNN's reporting on health and medical news for Starting Point with Soledad O'Brien, Anderson Cooper 360°, CNN documentaries, and anchors the weekend medical affairs program Sanjay Gupta MD. Gupta also contributes to CNN.com and CNNHealth.com.

ImmunoCellular's Phase IIb trial of ICT-107 is a double-blind, placebo-controlled, 2:1 randomized study designed to evaluate the safety and efficacy of ICT-107. The study is enrolling patients at medical institutions in collaboration with leading experts and opinion leaders in neuro-oncology. A transcript of the CNN show can be found at:

<http://edition.cnn.com/TRANSCRIPTS/1208/11/hcsg.01.html>

### About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company has commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. To learn more about the Company, please visit [www.imuc.com](http://www.imuc.com).

### Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that the prior safety and efficacy results for ICT-107 will not be confirmed in current or any subsequent trials of that product candidate in statistically significant larger patient populations. . Additional risks and uncertainties are described in IMUC's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

### **Contact Information:**

ImmunoCellular Therapeutics, Ltd.  
CEOcast, Inc.  
James Young  
Investor Relations  
Tel: (212) 732-4300  
Email: [jyoung@ceocast.com](mailto:jyoung@ceocast.com)

Source: ImmunoCellular Therapeutics, Ltd.